Compare Crispr Therapeutics AG (CRSP) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard S&P 500 ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 368.9× Crispr Therapeutics AG's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vanguard S&P 500 ETF for 55 Days on average.
| CRSP | VOO | |
|---|---|---|
Market Cap | $4.88B | $1.80T |
Volume | 2,861,747 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.97 | $716.17 |
52-Week Low | $44.34 | $580.93 |
Typical Hold Time | 77 Days | 55 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
VOO trades at $711.37, down 0.43% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional support despite a 46.9% increase in short interest reported by Defense World on October 3, 2026. Recent news highlights VOO's role as a core holding for long-term wealth building, with dividend payments scheduled for September 30, 2026.
VOO offers diversified exposure to S&P 500 companies with strong earnings growth projections of 35% for 2026. While short-term volatility may persist amid Federal Reserve policy uncertainty, the ETF remains well-positioned for investors seeking broad market participation. Key risks include potential earnings growth deceleration to 15% in 2027 and broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
